

Cochrane Learning live webinar: June 23rd 2020

RoB 2 Domain 1: Bias arising from the randomization process

Alexandra McAleenan and Jelena Savović
Population Health Sciences
Bristol Medical School

With special thanks to Julian Higgins, Jonathan Sterne, Matthew Page,
Roy Elbers, Barney Reeves, Asbjørn Hróbjartsson, Isabelle
Boutron, Luke McGuinness, Vincent Cheng and all RoB2 collaborators

Trusted evidence.
Informed decisions.
Better health.



Core group:

- Julian Higgins, Jonathan Sterne, Jelena Savović, Matthew Page, Asbjørn Hróbjartsson, Isabelle Boutron, Barney Reeves, Roy Elbers

Contributors:

- Natalie Blencowe, Marion Campbell, Mike Campbell, Christopher Cates, Vincent Cheng, Rachel Churchill, Mark Corbett, Nicky Cullum, Francois Curtin, Amy Drahota, Sandra Eldridge, Jonathan Emberson, Bruno Giraudeau, Jeremy Grimshaw, Miguel Hernán, Sally Hopewell, Daniela Junqueira, Peter Jüni, Jamie Kirkham, Toby Lasserson, Tianjing Li, Alexandra McAleenan, Stephen Senn, Sasha Shepperd, Ian Shrier, Nandi Siegfried, Lesley Stewart, Kate Tilling, Ian White, Penny Whiting

Further acknowledgements:

- Doug Altman, Henning Keinke Andersen, Mike Clarke, Jon Deeks, Sharea Ijaz, Geraldine MacDonald, Richard Morris, Mona Nasser, Nishith Patel, Jani Ruotsalainen, Holger Schünemann, Jayne Tierney

- Development of the revised tool for randomized trials (**ROB 2**) was supported by the UK **Medical Research Council** Network of Hubs for Trials Methodology Research (MR/L004933/1- N61)
- The original tool was developed with support from a **Cochrane Quality Improvement Project** grant and its evaluation and early revisions by the **Cochrane Methods Innovation Fund**



Session outline

- An overview of how bias can arise during the randomization process
 - Random allocation sequence generation
 - Allocation sequence concealment
- Evidence of problems during randomization from baseline imbalances
- Assessing risk of bias from the randomization process in RoB 2
- An example
- Resources available
- Questions



**Did you attend the Cochrane learning live webinar
“Introduction to RoB 2”?**

Poll



Have you used the original (2008 or 2011) version of the Cochrane risk of bias tool?

Poll



Have you used RoB 2 before?

Poll




Risk of bias in randomized trials

Bias arising from the randomization process

Bias due to deviations from intended intervention

Bias due to missing outcome data

Bias in measurement of the outcome




Experimental

Comparator

Outcome

Outcome




1.02	3.87
2.20	4.32
1.38	5.44



Bias in selection of the reported result

Risk of bias in randomized trials

Bias arising from the randomization process



Bias due to deviations from intended intervention



Experimental

Comparator

Bias due to missing outcome data



Bias in measurement of the outcome



Outcome

Outcome

1.02	3.87
2.20	4.32
1.38	5.44



Bias in selection of the reported result

Bias arising from the randomization process

Biased allocation to groups: *factors that predict the outcome influence group allocation*

Biased enrolment into study: *factors that predict the outcome influence whether a participant is enrolled into the study depending on predicted intervention assignment*

Adequate randomization and allocation concealment prevents both types of bias

Randomization: a two-step process

- **Generate an unbiased, unpredictable allocation sequence**
- **Conceal the allocation sequence**



Random allocation sequence

- allocation of participants to interventions occurs at the start of a trial
 - based on random assignment of participants into experimental or comparator intervention groups
 - avoids systematic differences in known or unknown prognostic factors between groups



Random allocation sequence

Adequate - unpredictable sequence

- these days, almost always computer-generated
- low tech - coin toss, shuffling cards or envelopes, throwing dice, drawing lots, random number tables
- minimization



Inadequate – predictable sequence

- ‘quasi-random’: alternate allocation, date of birth, day of visit, ID or record number
- non-random: choice of clinician or participant, test results, availability

Allocation sequence concealment

- occurs at the point of allocating participants to interventions
 - it is essential that when a person is recruited to the study, no-one can predict which group they will be allocated to
- ensures that the random sequence is implemented by preventing knowledge of the next allocation from:
 - changing the order of enrolment
 - affecting selection of who to enrol



Allocation sequence concealment

Adequate – cannot foresee

- central allocation (phone, web, pharmacy)
- sequentially numbered, sealed, opaque envelopes
- sequentially numbered, identical drug containers

Inadequate – can foresee

- random sequence known to staff in advance
- envelopes or packaging without all safeguards
- deducing last allocation(s) in fixed size blocks
- any non-random, predictable sequence



Subverting randomization

Examples from Schultz JAMA 1995;274(18):1456-8.

- Taking advantage of posting of the allocation sequence on a bulletin board.
- Opening unsealed envelopes, holding translucent envelopes up to a light, feeling the differential weight of envelopes, opening unnumbered envelopes until a desired treatment found.
- From appearance of tablets or labels

Reasons?

“They perhaps “know” the more effective treatment, so they may want certain patients to benefit or may want the results of a study to reveal what they believe to be valid.”



Evidence from baseline imbalance

- *Occasionally*, baseline imbalance provides evidence that randomization was not performed adequately
 - e.g. substantial differences between **intervention group sizes** (compared with intended allocation ratio)
 - e.g. **substantial excess in statistically significant differences** in baseline characteristics, clearly beyond that expected by chance
 - a few instances of “ $P < 0.05$ ” is not considered a substantial excess

Imbalances in baseline variables that have arisen due to chance do not lead to bias

If 20 variables are measured at baseline, would you expect at least one variable to have an imbalance leading to a $p < 0.05$?

Poll



If 20 variables are measured at baseline, would you expect at least one variable to have an imbalance leading to a $p < 0.05$?


Yes!

If we assume that the variables measured are uncorrelated (do not affect each other), we would expect 1 in 20 tests to have a $p < 0.05$.

More may occur by chance if factors are correlated (for e.g. a chance imbalance in age may lead to imbalance in other factors that are associated with age).



Anticoagulation for myocardial infarction



Wright 1948, Pocock 1991

What is the likely reason for unbalanced numbers allocated to the two groups in the anticoagulation for myocardial infarction trial?

Poll



What is the likely reason for unbalanced numbers allocated to the two groups in the anticoagulation for myocardial infarction trial?

We don't know for sure but...

there is the suspicion that investigators manipulated the allocation so that more patients were recruited on odd dates, when they would receive the new anticoagulant.



Baseline imbalance despite solid methods described



International Journal of Epidemiology, 2016, 223–231

doi: 10.1093/ije/dyv292

Advance Access Publication Date: 3 November 2015

Original article



Miscellaneous

**The effect of u
incidence of di
scuba diving: a**

**Shabbar I Ranapurwa
Kristen L Kucera,⁴ Ste**

¹Department of Epidemiology
Network, Durham, NC, USA, ³I
and ⁴Department of Exercise a

*Corresponding author. Injury Preve
E-mail: shabbarkaid@gmail.com

Accepted 5 October 2015

Assessed for enrolment
(*n* = UNKNOWN)

checklist.^{23,24} The trial had allocation concealment: the interns were only allowed to allocate the envelopes in the predetermined randomized order.²⁵ They did not know which envelope was intervention or control until they opened it on subsequent recruitment days.

Allocated to Intervention
(Pre-dive checklist)
(*n* = 693)

Allocated to control
(Post-dive log)
(*n* = 467)

Assessing bias arising from the randomization process in RoB 2



2011 Cochrane RoB tool

2011 tool included sequence generation and allocation concealment as separate domains

- (both under “*selection bias*”- not an appropriate term)
- Failure to implement either process adequately creates opportunities for either the enrolment into the study or the allocation of enrolled participants into groups to be influenced by prognostic factors

The end result is the same – unbalanced (biased) distribution of patients between groups

- It made sense to combine allocation sequence *generation* and allocation sequence *concealment* into a single domain

Risk of RoB 2 vs. 2011 Cochrane RoB tool

Additional signalling question about baseline imbalances.



Signalling questions and judgements


- **signalling questions** increase transparency
 - ‘Yes’, ‘Probably yes’, ‘Probably no’, ‘No’, ‘No information’
 - support each one with evidence/quotes/explanation
- algorithms map answers to signalling questions onto **risk of bias judgements**
 - ‘**Low risk of bias**’, ‘**Some concerns**’, ‘**High risk of bias**’
 - “Probably yes” = “Yes”, and “Probably no” = “No”
 - algorithms can be overridden
- a ‘High risk of bias’ judgement in any one domain puts the result at high risk of bias

Domain 1

Signalling Questions

Bias arising from the randomization process

- 1.1 Was the allocation sequence random?
 - Yes / Probably yes / Probably no / No / No information
- 1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?
 - Yes / Probably yes / Probably no / No / No information
- 1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?
 - Yes / Probably yes / Probably no / No / No information



An example



A Randomized, Parallel-Group, Observer-Blinded Clinical Trial of Strength Versus Aerobic Versus Relaxation Training for Patients With Mild to Moderate Depression

P: Patients with mild to moderate depression

I: Aerobic OR strength training (2x p.w. for 4 months)

C: Relaxation training (2x p.w. for 4 months)

O: Depressive symptoms, Absence from work, Cognitive function, Physical outcomes

Krogh et al. (2009) doi: [10.4088/jcp.08m04241](https://doi.org/10.4088/jcp.08m04241)

“This randomized, parallel-group, observer-blinded, superiority trial was carried out at a single location at Copenhagen University Hospital in Denmark. If the patients were considered eligible for inclusion, they were referred to randomization and exercise testing. Patients were randomly assigned to strength, aerobic, or relaxation training. Randomization was centralized and stratified according to medicine status: (1) not receiving antidepressant medication, (2) having received antidepressant medication for less than 6 weeks, or (3) having received antidepressant medication for more than 6 weeks. DEMO trial staff contacted the Copenhagen Trial Unit (CTU) by phone. Randomization was carried out by the CTU using computerized restricted randomization with a block size of 6. The block size and thus the allocation sequence were unknown to the DEMO trial staff.”

Was the allocation sequence random?

Poll



Was the allocation sequence concealed until participants were enrolled and assigned to interventions?

Poll



Suggested answers

Was the allocation sequence random: **Yes**

Was the allocation sequence concealed until participants were enrolled and assigned to intervention: **Yes**

Quote we chose:

"Randomization was centralized and stratified according to medicine status...DEMO trial staff contacted the Copenhagen Trial Unit (CTU) by phone. Randomization was carried out by the CTU using computerized restricted randomization with a block size of 6. The block size and thus the allocation sequence were unknown to the DEMO trial staff."



Extract of baseline characteristics table

	Strength (N = 55)	Aerobic (N = 55)	Relaxation (N = 55)
Female, N (%)	45 (81.8)	43 (78.2)	34 (61.8)
Age, mean (SD), y	41.9 (8.7)	38.1 (9.0)	36.7 (8.7)
Ethnicity, N (%)			
Caucasian	50 (90.9)	51 (92.7)	50 (90.9)
Other	5 (9.9)	4 (7.3)	5 (9.1)
Referred from, N (%)			
General practitioner	35 (63.6)	32 (58.2)	31 (56.4)
Private practice psychiatrist	15 (27.3)	11 (20.0)	16 (29.1)
Outpatient department	5 (9.1)	12 (21.8)	8 (14.5)
Depression			
17-Item Hamilton Rating Scale for Depression, mean (SD)	18.2 (3.6)	18.2 (3.8)	16.7 (3.8)
Montgomery-Asberg Depression Rating Scale, mean (SD)	22.0 (5.6)	22.9 (5.5)	21.6 (4.7)
DSM-IV criteria for major depressive disorder, N (%)	39 (70.9)	38 (69.1)	35 (63.6)
Beck Depression Inventory, ⁴² mean (SD)	30.6 (8.8)	30.5 (6.9)	31.8 (8.3)
14-Item Hamilton Rating Scale for Anxiety, mean (SD)	15.1 (5.7)	15.1 (5.6)	14.7 (5.1)
WHO-5, ⁴³ quality of life, mean (SD)	20 (12.3)	20 (10.1)	23 (11.5)
Using antidepressant medication, N (%)	39 (70.9)	37 (67.3)	38 (69.1)
Having used antidepressant medication > 6 wk, N (%)	35 (63.6)	35 (63.6)	32 (58.2)
Receiving psychotherapy, N (%)	24 (43.6)	28 (50.9)	25 (45.5)
Previous episodes of depression, mean (SD)	1.3 (2.0)	1.3 (1.9)	1.0 (1.7)
Time since diagnosis of current depression, mean (SD), mo	13.2 (21.7)	20 (37.4)	20.8 (30.2)
Work			
Unemployed, N (%)	23 (41.8)	30 (54.5)	20 (36.4)
Working full-time ~37 h/wk, N (%)	22 (40.0)	18 (32.7)	23 (41.8)
Working part-time ~20 h/wk, N (%)	8 (14.5)	6 (10.9)	10 (18.2)
Working < 20 h/wk, N (%)	2 (3.6)	1 (1.8)	2 (3.6)
Sick leave, N (%)	29 (52.7)	23 (41.8)	24 (43.6)
Percentage of days absent from work in last 10 d, mean (SD)	17.8 (31.5)	30 (34.7)	26.6 (35.3)
Cognitive skills, mean (SD)			
Verbal intelligence			
Danish Adult Reading Test	33.4 (9.2)	34.2 (8.7)	32.9 (8.1)

From Table 1

Page 794

doi:
10.4088/jcp.08
m04241

Did baseline differences between intervention groups suggest a problem with the randomization process?

Poll



Suggested answers


Did baseline differences between intervention groups suggest a problem with the randomization process: **Probably No**

Rationale:

- HAM-D17 score was lower in the relaxation group, which also had a higher proportion of male participants
- Although there are slight differences between the groups, these seem compatible with chance given that there are only 55 participants in each group and many variables were measured.



Risk of bias arising from the randomization process?



Suggested answers

Low

Rationale:

- Allocation sequence was adequately generated and concealed, and baseline imbalances appear to be compatible with chance.
- Your risk of bias rating will depend on how you answered the signalling questions.





Resources available



Cochrane Handbook (v 6)

- **Chapter 7** explains risk of bias issues in general
- **Chapter 8** provides a brief overview of the RoB 2 tool
- **MECIR** items summarize *Handbook* guidance





The screenshot shows the homepage of riskofbias.info. The header features the 'riskofbias.info' logo and the text 'Risk of bias tools'. A navigation menu on the left includes 'Welcome', 'RoB 2 tool', and 'ROBINS-I tool' (with a sub-item 'robvis (visualization tool)'). The main content area has a dark purple background with the text 'riskofbias.info' and a search icon. Below this, a welcome message is followed by a list of tools: 'RoB 2.0 tool (revised tool for Risk of Bias in randomized trials)', 'ROBINS-I tool (Risk Of Bias in Non-randomized Studies - of Interventions)', and 'robvis (visualization tool for risk of bias assessments in a systematic review)'. A feedback email address is provided. The footer contains copyright information for 2019 and the Creative Commons license details.

riskofbias.info

Risk of bias tools

^ Welcome

▼ RoB 2 tool

▼ ROBINS-I tool

robvis (visualization tool)

Welcome to our pages for risk of bias tools for use in systematic reviews.

- [RoB 2.0 tool \(revised tool for Risk of Bias in randomized trials\)](#)
- [ROBINS-I tool \(Risk Of Bias in Non-randomized Studies - of Interventions\)](#)
- [robvis \(visualization tool for risk of bias assessments in a systematic review\)](#)

Feedback is welcome to risk-of-bias@bristol.ac.uk

© 2019 by the authors.
RoB 2 and ROBINS-I licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Email risk-of-bias@bristol.ac.uk with feedback.

Revised Cochrane risk-of-bias tool for randomized trials (RoB 2)

Edited by Julian PT Higgins, Jelena Savović, Matthew J Page, Jonathan AC Sterne
on behalf of the RoB2 Development Group

22 August 2019

Dedicated to Professor Douglas G Altman, whose contributions were of fundamental importance to
development of risk of bias assessment in systematic reviews



This work is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

1	Introduction	2
1.1	Signalling questions	3
1.2	Risk-of-bias judgements	3
1.3	Specifying the nature of the effect of interest	5
2	Issues in implementation of RoB 2	6
2.1	Multiple assessments	6
2.2	The data collection process	7
2.3	Presentation of risk-of-bias assessments	7
2.4	Rapid assessments	7
3	Detailed guidance: preliminary considerations	8
4	Detailed guidance: bias arising from the randomization process	10
4.1	Background	10
4.2	Empirical evidence of bias arising from the randomization process	11
4.3	Using this domain of the tool	12
4.4	Signalling questions and criteria for judging risk of bias	16
5	Detailed guidance: bias due to deviations from intended interventions	21
5.1	Background	21
5.2	Empirical evidence of bias due to deviations from intended interventions	26
5.3	Using this domain of the tool	26

Questions

Trusted evidence.
Informed decisions.
Better health.

